Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35412607.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0738.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent work confirms a bench-to-bedside approach that circulating tumor DNA is associated with outcome and objective response to chemotherapy in patients with advanced leiomyosarcoma. Liquid biopsies may be used for risk stratification in future trials guiding treatment decisions by identifying patients who are likely to benefit from chemotherapy. See related article by Madanat-Harjuoja et al., p. 2579.
Medical subject headings
- Circulating Tumor DNA
- Leiomyosarcoma